Radar · Neurology in England
Best Neurology Companies in England, United Kingdom
The 136 best Neurology companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Markit.
By Riya SenguptaFinancials
136companies tracked
$3.5Bdisclosed funding
0unicorns
80have raised
FLIAR INTELLIGENCE · NEUROLOGY × ENGLAND
Our analysis of 50 Neurology companies
$7.4b in tracked funding; 74% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
74%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
187kcombined LinkedIn audience
39%of audience held by top 3
3companies hiring publicly (12 mo)
Ranked: Best Neurology companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Markit Developer of NMDA receptor modulators for neuropsychiatric and neurodevelopmental disorders | $750M | 157 mo ago | 1,030 | — | — | — | — |
| 2 | Spur Therapeutics Developer of gene therapies for debilitating chronic diseases | $401M | 70 mo ago | — | Naomi Aoki Founder & Principal | — | 16 patents Engineered stable beta‑glucocerebrosidase enzymes for lysosomal disease therapeutics | — |
| 3 | ReNeuron Group Developer of stem-cell-based therapeutics for stroke disability and critical limb ischemia | $326M | 98 mo ago | 34 | — | WordPressMySQLPHP+9 | 152 patents Cell therapy and exosome-based delivery of engineered stem cell-derived microparticles. | — |
| 4 | Mission Therapeutics Developer of small molecule inhibitors targeting specific disease associated enzymes 53Funding top 26%Moat top 26%Patents top 29%Innovation top 35% All 10 signals ▾Fundingtop 26% Moattop 26% Patentstop 29% Innovationtop 35% Talenttop 38% Growthtop 48% Markettop 50% Globalbottom 42% Fin. healthbottom 31% Newsbottom 21% Funding: Raised $179M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 305 patents rank vs industry peers · Fliar Intelligence Index 53/100 | $179M | 8 mo ago | 45 | Keith Menear Co-Founder | — | 305 patents Small-molecule USP30 deubiquitinase inhibitors for mitochondrial disease, cancer, and fibrosis | — |
| 5 | OMass Therapeutics Developer of therapeutics for immunological and orphan diseases | $166M | 37 mo ago | 36 36 → 78 (+117%) | Carol Robinson Co-Founder | WordPressApple iCloud MailMySQL+21 | 16 patents Small‑molecule modulators of MC2R, GPR65, and SMO receptors for endocrine and oncology therapies. | 1 job opening |
| 6 | Evox Therapeutics Developer of exosome-based therapeutics for severe neurological and rare diseases | $156M | 64 mo ago | 73 73 → 40 (-45%) | Samir Andaloussi Co-Founder | WordPressMySQLPHP+15 | 193 patents Engineered extracellular vesicle/exosome platforms for targeted delivery of RNA, proteins, and CRISPR tools | — |
| 7 | Beckley Psytech Developer of rapid-acting psychedelic medicines for mental health disorders | $153M | 29 mo ago | 1 | Cosmo Mellen Co-Founder & CEO | Webflow EcommerceWebflowSwiper+15 | 78 patents Formulating and delivering 5‑MeO‑DMT as pharmaceutical/ digital therapies for depression and addiction. | — |
| 8 | COMPASS Pathways Developer of therapies for treating mental disorders | $109M | 34 mo ago | 42 | Lars Wilde Co-Founder | WordPressPleskApple iCloud Mail+25 | 23 patents Patents concentrated in chemistry & materials | — |
| 9 | Proximagen Small molecules for neurodegenerative disorders, including Parkinson’s and Alzheimers. | $96M | 176 mo ago | 28 | Peter Jenner Founder | — | 349 patents Small-molecule SSAO and CXCR4 receptor inhibitors for therapeutic applications | — |
| 10 | Alchemab Developer of antibody therapeutics for treating oncology and neurodegenerative conditions 45Funding top 28%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 28% Talenttop 28% Moattop 31% Growthtop 35% Globalbottom 37% Marketbottom 34% Techbottom 33% Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) Talent: 4 named leaders on record · 4 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $83M | 9 mo ago | 8 | Jane Osbourn Co-Founder & CEO | WordPress Block EditorWordPressMySQL+14 | — | — |
| 11 | AviadoBio Developer of gene therapies for neurodegenerative disorders | $80M | 54 mo ago | 38 38 → 70 (+84%) | Do Lee Co-Founder | WordPressApple iCloud MailMicrosoft 365+29 | 3 patents Antisense nucleic‑acid therapies targeting SOD1 for ALS and CNS drug delivery platforms. | 1 launch · 1 partnership |
| 12 | Heptares Develops small molecule drugs targeting GPCRs | $62M | 119 mo ago | 168 | Malcolm Weir Co-Founder & CEO | — | — | — |
| 13 | Phagenesis Developer of medical devices for the treatment of Neurogenic dysphagia | $62M | 27 mo ago | 22 | Conor Mulrooney Co-Founder & COO | WordPressMySQLPHP+26 | 126 patents Bioelectronic therapeutic devices and wearable medical accessories for neuromodulation and dysphagia treatment | — |
| 14 | LoQus23 Developer of oral small molecule therapies to treat neurodegenerative diseases | $61M | 20 mo ago | 1 | — | — | — | — |
| 15 | AstronauTx Developer of therapeutics for neurodegenerative disorders | $61M | 32 mo ago | 5 | Ruth Mckernan Co-Founder | WordPressMySQLPHP+13 | — | 1 award |
| 16 | WaveBreak Developer of small molecule therapeutics for neurological disorders | $60M | 26 mo ago | 51 | Bart Henderson CEO | — | — | — |
| 17 | CoMind Provider of a non-invasive brain-computer interface solution for various industries 55Growth top 11%News top 24%Funding top 29%Moat top 42% All 9 signals ▾Growthtop 11% Newstop 24% Fundingtop 29% Moattop 42% Partnerstop 45% Talentbottom 49% Marketbottom 38% Globalbottom 37% Techbottom 36% Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo rank vs industry peers · Fliar Intelligence Index 55/100 | $60M | 8 mo ago | 36 36 → 81 (+125%) | James Dacombe Co-Founder & CEO | Framer SitesApple iCloud MailGoogle Workspace+8 | — | — |
| 18 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | 9 | Vicente Gonzalez Co-Founder | — | — | — |
| 19 | Levicept Developer of therapeutics for the treatment of chronic pain | $51M | 57 mo ago | 6 | Simon Westbrook CSO and Founder | WordPress Site EditorWordPressMySQL+10 | 105 patents Patents concentrated in chemistry & materials | — |
| 20 | Small Pharma Developer of psychedelic-based therapeutics for mental health conditions | $49M | 63 mo ago | 8 | — | — | 148 patents Deuterated psychedelic compounds and specialized delivery formulations for psychiatric therapies | — |
| 21 | GW Pharma Developer of cannabinoid medicines for MS spasticity, cancer pain and childhood epilepsy | $46M | 111 mo ago | 326 | — | — | 1,120 patents Cannabinoid-based epilepsy treatments and probiotic bacterial strain formulations | — |
| 22 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 29 mo ago | 46 | — | WordPressMySQLPHP+15 | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 23 | Convergence Pharma Develops novel analgesics with better efficacy and less side effects. | $35M | 188 mo ago | 9 | — | — | — | — |
| 24 | Trimtech Therapeutics They develop treatments for CNS and inflammatory disorders | $31M | 15 mo ago | — | Leo James Co-Founder | WordPressMySQLPHP+13 | — | 1 award |
| 25 | Kesmalea Developer of protein homeostasis modulators for therapeutic applications | $30M | 21 mo ago | 5 | Harry Finch Founder Director | WordPressMySQLPHP+13 | — | — |
| 26 | Oxford Endovascular Developer of treatment device for neurovascular disease | $23M | 25 mo ago | 7 | Andrew Moor Director of R&D | — | 21 patents Self‑expanding intravascular stent tubes and delivery systems for endovascular procedures. | — |
| 27 | NRG Therapeutics Developer of drugs for neurodegenerative diseases | $18M | 9 mo ago | 5 | Neil Miller Co-Founder and CEO | CMS Made SimplePleskApple iCloud Mail+16 | 39 patents Mitochondrial permeability transition pore inhibitors for neuro‑protective therapeutics | — |
| 28 | Endlyz Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases 24Funding top 32%Tech bottom 49%Talent bottom 49%Global bottom 48% All 5 signals ▾Fundingtop 32% Techbottom 49% Talentbottom 49% Globalbottom 48% Marketbottom 25% Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel rank vs industry peers · Fliar Intelligence Index 24/100 | $17M | 2 mo ago | — | Joanna Wolak Co-Founder & CEO | Node.jsTailwind CSSReact+10 | — | — |
| 29 | OVM Therapeutic peptide vaccines for cancer | $12M | 19 mo ago | 5 | Shisong Jiang Founder & Director | — | — | — |
| 30 | Cytox Developer for prognostic tests for assessing the risk of dementia | $12M | 82 mo ago | 12 | — | — | — | — |
| 31 | Scripta Therapeutics Developer of therapeutics modulating transcription factor activity for disease treatment 27Funding top 36%Talent top 38%Tech bottom 49%Global bottom 45% All 5 signals ▾Fundingtop 36% Talenttop 38% Techbottom 49% Globalbottom 45% Marketbottom 25% Funding: Raised $11.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 27/100 | $12M | 7 mo ago | — | Jerry Huang Co-Founder & VP Machine Learning | Framer SitesApple iCloud MailReact+13 | — | — |
| 32 | Pangea Botanica Developing and discovering nature-inspired therapeutics | $12M | 38 mo ago | 8 | Julia Wilde Co-Founder | — | 2 patents Accelerated hardware implementations for high‑speed cosine arithmetic operations | — |
| 33 | Harness Therapeutics Developer of therapeutics for neurological disorders | $11M | 30 mo ago | 5 | Jan Thirkettle Chief Executive Officer | ProcessWirePHPjQuery+8 | — | — |
| 34 | OKYO Pharma Developer of therapeutics for the treatment of dry eye disease and chronic pain management | $10M | 11 mo ago | 6 | Gary Jacob Chief Executive Officer | WordPressMySQLPHP+10 | — | 1 expansion |
| 35 | Neurofenix Manufacturer of medical devices for neurorehabilitation | $7M | 45 mo ago | 6 | — | WebflowReactstyled-components+22 | 6 patents Rehabilitation devices for motor training and therapy | — |
| 36 | Bloomsbury Genetic Therapies Provider of gene therapy commercialization services | $6M | 46 mo ago | 4 | Adrien Lemoine Co-Founder & CEO | — | — | — |
| 37 | AWAKN CRO focused on early stage clinical trial research | $6M | 15 mo ago | 3 | — | WordPressMySQLPHP+30 | — | — |
| 38 | BioCorteX Developer of human-microbiome platform for drug development | $5M | 38 mo ago | 13 | Nik Sharma Co-Founder & CEO | — | — | 1 award |
| 39 | Isogenix Developer of precision therapies targeting protein isoforms for neuromuscular and neurological diseases | $5M | 38 mo ago | — | Catheryn Lim Co-Founder | — | — | — |
| 40 | Monument Therapeutics Developer of targeted treatments for the treatment of psychiatry and neurological diseases | $5M | 15 mo ago | 7 | Sheryl Caswell Co-Founder & CDO | WordPressMySQLPHP+19 | — | — |
| 41 | Walk With Path Smart footwear for reducing the risk of fall | $4M | 46 mo ago | 2 | Lise Pape Founder | Cart FunctionalityShopifyBootstrap+27 | — | — |
| 42 | QV Bioelectronics Manufacturer of electrotherapy devices for treating brain tumors | $4M | 4 mo ago | 6 | Christopher Bullock Co-Founder & CTO | — | 25 patents Implantable bioelectronic devices for neural stimulation and monitoring | — |
| 43 | Crucible Therapeutics Developer of RNA-targeting therapies for neurodegenerative diseases | $3M | 12 mo ago | — | Guillaume Hautbergue Chief Scientific Officer | — | — | — |
| 44 | Solvonis Therapeutics Developer of novel therapeutics for addiction and mental health disorders | $3M | 8 mo ago | — | Anthony Tennyson Co-Founder & Chief Executive Officer | Framer SitesReactPriority Hints+6 | — | — |
| 45 | Aptorum Group Developer of small molecular therapeutics for multiple disorders | $3M | 42 mo ago | 26 | Ian Huen Founder & CEO | — | — | — |
| 46 | Newrotex Provider of silk-based solutions for the treatment of peripheral nerve injuries | $3M | 39 mo ago | 3 | Fritz Vollrath Co-Founder | WordPressMySQLPHP+22 | 10 patents Peripheral nerve repair conduits for enhanced regeneration of damaged nerves | 1 award |
| 47 | Cerca Provider of a brain scanning medical imaging device for neurological and mental health diagnosis 21Moat top 48%Funding top 49%Talent bottom 49%Tech bottom 48% All 7 signals ▾Moattop 48% Fundingtop 49% Talentbottom 49% Techbottom 48% Fin. healthbottom 42% Globalbottom 32% Marketbottom 28% Moat: Editorial + unicorn rating 5/10 · 6 curated direct competitors tracked Funding: Raised $2.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $3M | 1 mo ago | 7 | David Woolger Co-Founder & CEO | WebflowHubSpotcore-js+15 | — | 1 job opening · 1 expansion |
| 48 | UpFront Diagnostics Developer of rapid diagnostic tests for stroke detection | $2M | 13 mo ago | 3 | Edoardo Gaude Co-Founder & Chief Scientific Officer | — | — | 1 award |
| 49 | MYndspan Platform offering detailed reports on cognitive function and brain connectivity | $2M | 14 mo ago | 5 | Caitlin Baltzer Co-Founder | PrismicNode.jsReact+12 | — | — |
| 50 | Reneural Developer of a neurorehabilitation platform integrating virtual reality for stroke recovery | $617K | 19 mo ago | — | Victor Harabari Founder & CEO | — | — | — |
Top 12 Neurology companies in England
#1
Series D · Cambridge, England · founded 2011 · 45 employees$178.9Mraised▾
Series D · Cambridge, England · founded 2011 · 45 employees
Developer of small molecule inhibitors targeting specific disease associated enzymes. These therapeutic candidates focus on the regulation of cellular quality control processes to address neurodegenerative conditions, heart disease, kidney disease, and fibrosis. The research centers on the modulation of protein degradation pathways to influence disease progression.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 26%Moat
top 26%Patents
top 29%Innovation
top 35%Talent
top 38%Growth
top 48%Funding: Raised $179M across 9 rounds · 9 rounds over 15 yrs (0.6/yr) · Last round Series D (Oct 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 305 patents · Soonicorn
Patents: 305 patents matched (strict assignee match) · 106 filings since 2022 vs 191 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 9k LinkedIn followers — 4.9% of this cohort's audience
Activity (LinkedIn): 1 awards announced in 12 mo
Funding rounds
- Oct 2025Series D$13.3M
- Jul 2024Grant (prize money)$5.2M
- Mar 2024Series D$32.2M
- Jan 2021Series C$3.7M
Founders & team
Investors
Innovate UK, Imperial Innovations, Woodford Investment Management, Roche, Pfizer Venture Investments, Sofinnova Partners
#2
Series B · London, England · founded 2021$17.3Mraised▾
Series B · London, England · founded 2021
Developer of small-molecule therapeutics targeting lysosomal dysfunction in neurodegenerative diseases. The company focuses on developing disease-modifying therapies to restore endo-lysosomal function and reduce neurodegeneration. Their pipeline includes small molecule modulators targeting ATP13A2 and ATP10B lysosomal transporters, both critical for maintaining neuronal health. Initial clinical indications target genetic subsets of Parkinson's disease, with plans to expand into sporadic Parkinson's and other neurodegenerative disorders. The approach aims to address the underlying causes of these diseases rather than just managing symptoms.
Fliar Intelligence Index™ 24how this company ranks against its industry peers
Funding
top 32%Tech
bottom 49%Talent
bottom 49%Global
bottom 48%Market
bottom 25%Funding: Raised $17.3M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series B (Mar 2026)
Tech: 13 technologies across 4/8 capability areas · Cloud: Vercel · Security: Hsts
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Funding rounds
- Mar 2026Series B$17.3M
Founders & team
Investors
SV Health Investors
#3
Series A · London, England · founded 2019 · 8 employees$82.7Mraised▾
Series A · London, England · founded 2019 · 8 employees
Developer of antibody therapeutics for treating oncology and neurodegenerative conditions. This organization identifies drug targets by analyzing patient antibody repertoires through deep sequencing and computational analysis. The process focuses on identifying convergent protective antibody responses found in individuals who demonstrate resilience to specific diseases. These findings facilitate the creation of therapeutic candidates intended for clinical application.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Funding
top 28%Talent
top 28%Moat
top 31%Growth
top 35%Global
bottom 37%Market
bottom 34%Funding: Raised $82.7M across 3 rounds · 3 rounds over 7 yrs (0.4/yr) · Last round Series A (Sep 2025)
Talent: 4 named leaders on record · 4 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 11k LinkedIn followers — 6.1% of this cohort's audience
Activity (LinkedIn): 1 partnerships · 3 awards (incl. Natural Portfolio) announced in 12 mo
Funding rounds
- Sep 2025Series A$32M
- Dec 2022Grant (prize money)$2.1M
- 2021Grant (prize money)—
- Apr 2021Series A$82.7M
Founders & team
Investors
Innovate UK, SV Health Investors, RA Capital Management, Lightstone Ventures, DCVC, DHVC
Tech stack
DocusignGodaddyGoogle AnalyticsGoogle Font ApiJqueryJquery Migrate
#4
Series A · London, England · founded 2017 · 36 employees$60Mraised▾
Series A · London, England · founded 2017 · 36 employees
Provider of a non-invasive brain-computer interface solution for various industries. It enables users to develop, design, measure, study, record, process, analyze, manage, and control brain data for decision-making. Its offering includes application development, research, neuroimaging, and stimulation technologies. It caters to the health and manufacturing industries.
Fliar Intelligence Index™ 55how this company ranks against its industry peers
Growth
top 11%News
top 24%Funding
top 29%Moat
top 42%Partners
top 45%Talent
bottom 49%Growth: Headcount 15 → 36 (+140%) across vintages · Fresh capital in last 24 mo
News: 7 BI events in 12 mo (of 7 tracked, 2 types) · 4 high-value events (IPO/M&A/funding/contracts) in 12 mo · Top themes: Funding, Regulatory
Funding: Raised $60.0M across 1 rounds · 1 rounds over 3 yrs (0.3/yr) · Last round Series A (Oct 2025)
Audience (LinkedIn): 11k LinkedIn followers — 5.8% of this cohort's audience
Funding rounds
- Oct 2025Series A$60M
- 2023Seed—
Founders & team
Investors
Angelini Ventures, LocalGlobe, Octopus Ventures, Crane Venture Partners, Backed, Entrepreneur First
Tech stack
Apple Icloud MailFramer SitesGodaddyGoogle Font ApiGoogle WorkspaceHsts
#5
Series A · England · founded 2020 · 7 employees$2.5Mraised▾
Series A · England · founded 2020 · 7 employees
Provider of a brain scanning medical imaging device for neurological and mental health diagnosis. The company has developed a wearable helmet that uses magnetic fields to scan the brain and generate brain functions to diagnose any neurological or psychiatric conditions. The tool provides real-time data for brain networks for cognitive demands for healthcare professionals to aid in the process of treatment and diagnosis.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Moat
top 48%Funding
top 49%Talent
bottom 49%Tech
bottom 48%Fin. health
bottom 42%Global
bottom 32%Moat: Editorial + unicorn rating 5/10 · 6 curated direct competitors tracked
Funding: Raised $2.5M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) · Last round Series A (Apr 2026)
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Laboratory Technician, Project Manager
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Apr 2026Series A$5.1M
- Feb 2024Seed$2.5M
Founders & team
Investors
Guinness Ventures, Nottingham Technology Ventures
#6
Series B · Cambridge, England · founded 2018 · 5 employees$18.4Mraised▾
Series B · Cambridge, England · founded 2018 · 5 employees
Developer of drugs for neurodegenerative diseases.It is involved in developing the small molecule-based drug which can penetrant mitochondrial permeability and transition pore inhibitors to safeguard dopamine cells for neurodegenerative diseases like Parkinson’s disease, Alzheimer’s disease, and motor neuron disease
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.3% of this cohort's audience
Funding rounds
- Sep 2025Series B$67.5M
- Feb 2023Grant (prize money)$500K
- Nov 2022Series A$18.4M
- May 2022Grant (prize money)$3.4M
Founders & team
Investors
Gov, The Michael J. Fox Foundation, Omega Funds, Brandon Capital, Parkinsons Virtual Biotech, SV Health Investors
Tech stack
Apple Icloud MailBootstrapCivicCms Made SimpleCore-JsFont Awesome
#7
Seed · Oxford, England · founded 2025$11.9Mraised▾
Seed · Oxford, England · founded 2025
Developer of therapeutics modulating transcription factor activity for disease treatment. It focuses on identifying and manipulating master controllers of biology. The company utilizes AI/ML models to reveal novel therapeutics. It validates results in patient-derived models, initially targeting neurodegenerative diseases.
Fliar Intelligence Index™ 27how this company ranks against its industry peers
Funding
top 36%Talent
top 38%Tech
bottom 49%Global
bottom 45%Market
bottom 25%Funding: Raised $11.9M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Seed (Nov 2025)
Talent: 2 named leaders on record · 2 C-suite/founder profiles curated
Tech: 16 technologies across 4/8 capability areas · Cloud: Cloudflare · Security: Cloudflare Bot Management, Hsts
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 1 partnerships (incl. TuneLab) announced in 12 mo
Funding rounds
- Nov 2025Seed$11.9M
Founders & team
Investors
Oxford Science Enterprises, Apollo Health Ventures, AlbionVC, YZR Capital, Parkwalk, Oxford University Innovation
Tech stack
Apple Icloud MailCloudflareCloudflare Bot ManagementFramer SitesGoogle AnalyticsGoogle Font Api
#8
Series A · Manchester, England · founded 2019 · 6 employees$3.6Mraised▾
Series A · Manchester, England · founded 2019 · 6 employees
Manufacturer of electrotherapy devices for treating brain tumors. The company's flagship product is GRACE, an implanted device that delivers electric field therapy directly to the tumour resection margins where GBM recurrence takes place.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Jan 2026Grant (prize money)—
- Jan 2026Series A$6.1M
- Apr 2023Grant (prize money)$1.1M
- Jan 2023Seed$2.4M
Founders & team
Investors
Consilience Ventures, SOSV, Catapult Ventures, Ukri, Northern Gritstone, Elbow Beach Capital
#9
Public · London, England · founded 2018 · 6 employees$10.4Mraised▾
Public · London, England · founded 2018 · 6 employees
Developer of therapeutics for the treatment of dry eye disease and chronic pain management. The company's lead candidate is OK-101 to treat ocular diseases, including dry eye, uveitis, allergic conjunctivitis and ocular pain. It is also developing a non-opioid analgesic BAM8 utilizing oral and nasal formulations for the management of chronic pain.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers · 74 engagements/post (1.7× cohort median)
Activity: 2 expansions announced in 12 mo
Funding rounds
- Jul 2025Grant (prize money)$1.9M
- Jan 2025Post IPO$1.4M
- Sep 2020Post IPO$659.5K
- Aug 2020Post IPO$1.9M
Founders & team
Tech stack
DiviGodaddyGoogle Font ApiHttp/3LitespeedLitespeed Cache
#10
Seed · Cambridge, England · founded 2023$31Mraised▾
Seed · Cambridge, England · founded 2023
They develop treatments for CNS and inflammatory disorders. The company creates highly specific degraders that selectively target and remove toxic proteins. This approach is based on research into TRIM21, a ubiquitin ligase, to treat protein aggregation disorders. They aim to provide therapeutic benefits for intractable CNS and inflammatory diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.3% of this cohort's audience
Activity: 1 awards announced in 12 mo
Funding rounds
- Mar 2025Seed$31M
Founders & team
Investors
Cambridge Innovation Capital, SV Health Investors, M Ventures, Pfizer Ventures, Lilly, MP Healthcare Venture Management
Tech stack
CookieyesGodaddyHttp/3JqueryJquery MigrateMicrosoft 365
#11
Series A · Cambridge, England · founded 2019 · 1 employees$61.3Mraised▾
Series A · Cambridge, England · founded 2019 · 1 employees
Developer of oral small molecule therapies to treat neurodegenerative diseases. The company is focused on using a structure-based approach to design small-molecule drugs targeting aberrant DNA mismatch repair for the treatment of Huntington’s Disease and other triplet repeat disorders.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 2k LinkedIn followers
Funding rounds
- Oct 2024Series A$46.6M
- Nov 2021Seed$9.4M
- 2019Seed$5.3M
Investors
SV Health Investors, Novartis Venture Fund, Forbion, Dementia Discovery Fund
#12
Public · London, England · founded 2017$3Mraised▾
Public · London, England · founded 2017
Developer of novel therapeutics for addiction and mental health disorders. This company focuses on creating new medicines to address the limitations of existing treatments for these conditions. The initial therapeutic focus is on post-traumatic stress disorder (PTSD). The goal is to provide effective solutions that improve patient outcomes and reduce the significant societal and economic burdens associated with these disorders.
Funding rounds
- Oct 2025Post IPO$1.7M
- Jul 2025Post IPO$1.4M
Founders & team
Tech stack
Framer SitesGodaddyGoogle Font ApiHstsHttp/3Microsoft 365
Funding & investor landscape
$3.5Btotal disclosed funding
80companies funded
204disclosed rounds
2rounds last 90 days
Most active investors
Gov10 rounds
Notable founders
Keith Menear
Co-Founder · Mission Therapeutics
Anker Lundemose
CEO · Mission Therapeutics
Joanna Wolak
Co-Founder & CEO · Endlyz
Jane Osbourn
Co-Founder & CEO · Alchemab
Ruth Mckernan
Co-Founder · Alchemab
James Dacombe
Co-Founder & CEO · CoMind
David Woolger
Co-Founder & CEO · Cerca
Neil Miller
Co-Founder and CEO · NRG Therapeutics
Jerry Huang
Co-Founder & VP Machine Learning · Scripta Therapeutics
Peter Hamley
Co-Founder & CEO · Scripta Therapeutics
Christopher Bullock
Co-Founder & CTO · QV Bioelectronics
Richard Fu
Co-Founder · QV Bioelectronics
Prism market signals · United Kingdom · country-scoped Prism corpus, 1,681,470 docs
Market landscape — 10 sub-themes by coverage
Share of Neurology coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH SIGNALS · United Kingdom
How research on Neuroscience & Neurotech is moving in the United Kingdom
A read on the academic research around Neuroscience & Neurotech — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,968 United Kingdom-affiliated papers.
research sentiment over time
200820172026
enthusiastic · positive · guarded tone
Tone is overwhelmingly optimistic and intensifying — the enthusiastic (strongly-positive) share moved 20% → 41% across 2008–2026.
top research entities
- University College London388
- University of Oxford310
- National Hospital for Neurology and Neurosurgery238
- Imperial College London194
- MRC Brain Network Dynamics Unit185
leading researchers
Marwan Hariz · Ludvic Zrinzo · Alek Pogosyan · Tipu Z. Aziz · Patricia Limousin · Alexander L. Green · Thomas Foltynie · Harith Akram
▲
Breakthroughs303 · 15%
▲ 13%→17% share
▲1.3× share momentum9 median citations48% since 2021mostly methods-led
Optogenetics research surged from 1 to 14 papers, signalling a rapidly emerging precision-stimulation frontier in UK neurotech.
rising sub-themes (early→recent)
- Neuromodulation2→23
- Stimulation16→35
- Deep brain stimulation44→59
- Neurostimulation7→22
- Optogenetics1→14
Newly emergingWearable computer 0→6 · Electrophysiology 0→6 · Photostimulation 0→5
Landmark Dichotomous Organization of the External Globus Pallidus · 447 cites
◆
Advancements941 · 48%
47%→47% share
▲1.0× share momentum9 median citations42% since 2021mostly empirical
Vagus nerve stimulation research nearly quadrupled (6->22), reflecting intensifying UK clinical translation efforts.
rising sub-themes (early→recent)
- Neuromodulation19→57
- Neurostimulation37→59
- Brain stimulation15→35
- Vagus nerve stimulation6→22
- Disease13→28
Newly emergingWakefulness 0→8 · Ictal 0→6 · Rhythm 0→6
Landmark Dorsal and Ventral Attention Systems · 1,435 cites
▼
Concerns456 · 23%
▼ 26%→23% share
▼0.9× share momentum15 median citations41% since 2021mostly empirical
Neuroprosthetics safety research sextupled (2->12), flagging growing scrutiny over implantable device risks.
rising sub-themes (early→recent)
- Neuromodulation14→34
- Neuroprosthetics2→12
- Neurostimulation18→28
- Meta-analysis1→8
- Brain stimulation12→19
Newly emergingMEDLINE 0→5
Landmark The anatomical basis for transcutaneous auricular vagus nerve stimulation · 530 cites
RESEARCH HOTSPOTS · United Kingdom
Where neurotech is researched across United Kingdom
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
London804 · +0.34
Oxford341 · +0.41
Cambridge79 · +0.38
Manchester53 · +0.22
Bristol39 · +0.39
Glasgow34 · +0.25
Birmingham31 · +0.22
Edinburgh19 · +0.34
PATENT SIGNAL · United Kingdom
Who's filing neurotech patents in the United Kingdom
United Kingdom neurotech patent filing is accelerating — 134 filings from 71 assignees (2016–2025), led by Galvani Bioelectronics, Bioinduction, UNIV Newcastle; annual filings 5→18.
134 filings71 assigneespeak 24/yr2016–2025
filing momentum (YoY 2016–2025)
top patent filers
- Galvani Bioelectronics54
- Bioinduction15
- UNIV Newcastle9
- Imperial College Innovations8
- UNIV Oxford Innovation8
- Goroszeniuk Teodor7
- Smith & Nephew7
- BIOS Health5
Common questions
How many Neurology companies are there in England, United Kingdom?
Radar tracks 136 indexable Neurology companies headquartered in England, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Neurology companies in England, United Kingdom?
The Neurology companies in England, United Kingdom on this list have raised a combined $3.5B in disclosed equity funding across 80 funded companies.
Which is the highest-funded Neurology company in England, United Kingdom?
Markit is the highest-funded Neurology company in England, United Kingdom, with $750M in disclosed equity funding.
How many Neurology companies in England, United Kingdom are funded?
80 of the 136 Neurology companies in England, United Kingdom on this list have disclosed at least one equity funding round.
How many Neurology unicorns are there in England, United Kingdom?
None of the Neurology companies in England, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in England, United Kingdom Neurology companies?
The most active investors in England, United Kingdom Neurology companies on this list include Europa, SV Health Investors, Gov, Oxford University Innovation, EIC Fund.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.